A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia

Inclusion Criteria

• •Have a diagnosis of primary ITP, defined as isolated thrombocytopenia not associated with another known disease process
• •Have documented history of response, defined as 2 or more platelet counts greater than or equal to 50,000/microliter (μL), to at least 1 prior line of therapy. Splenectomy is considered a line of therapy
• •Have relapsed or treatment-resistant primary ITP, with no available therapies known to provide clinical benefit
• •Have a platelet count less than 30,000/μL on 2 occasions more than 5 days apart in the 15 days before randomization
• •Have adequate liver, renal, and hematologic functions as defined by a table
• •Are willing to follow contraception requirements